secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viracta Therapeutics, Inc. (—)
CIK:        0001061027
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-057130
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viracta Q1 net loss $9.1M; positive NAVAL-1 trial ORR 50% in EBV+ PTCL
----------------------------------------------------------------------

- Net loss $9.1M ($0.23/shr) vs $12.2M in Q1 2023; cash $39.6M sufficient into late Q1 2025.
- NAVAL-1 trial: Nana-val ORR 50%, complete response rate 20% in R/R EBV+ PTCL (n=10); median DoR maturing.
- Plan to meet FDA mid-2024 for accelerated approval; Stage 1+2 data expected Q3 2024.
- PMDA endorsed direct Japan enrollment into NAVAL-1 without prior Phase 1 safety study.
- Phase 1b/2 solid tumor study: RP2D expected H2 2024; dose-optimization cohort by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061027/000095017024057130/0000950170-24-057130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061027/000095017024057130/virx-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-057130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer